[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1251862A1 - 治療癌症的方法和組合物 - Google Patents

治療癌症的方法和組合物

Info

Publication number
HK1251862A1
HK1251862A1 HK18110565.4A HK18110565A HK1251862A1 HK 1251862 A1 HK1251862 A1 HK 1251862A1 HK 18110565 A HK18110565 A HK 18110565A HK 1251862 A1 HK1251862 A1 HK 1251862A1
Authority
HK
Hong Kong
Prior art keywords
compositons
methods
treating cancer
cancer
treating
Prior art date
Application number
HK18110565.4A
Other languages
English (en)
Inventor
沙德哈克．森古普塔
普拉卡什．桑帕斯
理查德．P．容漢斯
Original Assignee
普拉斯派克特查特凱爾Rwmc有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 普拉斯派克特查特凱爾Rwmc有限責任公司 filed Critical 普拉斯派克特查特凱爾Rwmc有限責任公司
Publication of HK1251862A1 publication Critical patent/HK1251862A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
HK18110565.4A 2014-12-02 2018-08-16 治療癌症的方法和組合物 HK1251862A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086346P 2014-12-02 2014-12-02
PCT/US2015/063267 WO2016089916A1 (en) 2014-12-02 2015-12-01 Methods and compositons for treating cancer

Publications (1)

Publication Number Publication Date
HK1251862A1 true HK1251862A1 (zh) 2019-04-26

Family

ID=56078487

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110565.4A HK1251862A1 (zh) 2014-12-02 2018-08-16 治療癌症的方法和組合物

Country Status (18)

Country Link
US (2) US9650428B2 (zh)
EP (1) EP3227317A4 (zh)
JP (1) JP2017537622A (zh)
KR (1) KR20180041087A (zh)
CN (1) CN107709353A (zh)
AR (1) AR102879A1 (zh)
AU (1) AU2015355084A1 (zh)
BR (1) BR112017011771A2 (zh)
CA (1) CA2969714A1 (zh)
EA (1) EA201791210A1 (zh)
HK (1) HK1251862A1 (zh)
IL (1) IL252610A0 (zh)
MX (1) MX2017007272A (zh)
PH (1) PH12017501031A1 (zh)
SG (2) SG11201704519YA (zh)
TW (1) TW201636425A (zh)
UY (1) UY36418A (zh)
WO (1) WO2016089916A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112871A1 (en) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic il-13 polypeptides
EP3227317A4 (en) 2014-12-02 2018-04-25 Roger Williams Hospital Methods and compositons for treating cancer
CN115927474A (zh) * 2015-06-19 2023-04-07 塞巴斯蒂安·科博尔德 Pd-1-cd28融合蛋白及其在医学中的用途
SG10201912734PA (en) * 2015-08-05 2020-02-27 Yoo Young Pharm Co Ltd Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
US20200095301A1 (en) * 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
WO2018148224A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
AU2018256436A1 (en) 2017-04-19 2019-11-07 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
MX2020005251A (es) * 2017-11-20 2021-01-29 Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center Composiciones para mejorar la funcionalidad de células car-t y uso de las mismas.
MX2020006689A (es) * 2017-12-20 2020-11-06 Poseida Therapeutics Inc Composiciones de vcar y metodos de uso.
EP3740217A4 (en) 2018-01-22 2021-11-10 Endocyte, Inc. METHOD OF USE FOR CAR-T CELLS
CN110144326A (zh) * 2018-02-12 2019-08-20 深圳宾德生物技术有限公司 一种靶向性抗肿瘤t细胞及其制备方法和应用
CN110157674A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
CN108440674A (zh) * 2018-04-28 2018-08-24 杭州荣泽生物科技有限公司 一种Trop-2特异性嵌合抗原受体细胞制备及其用途
BR112023004433A2 (pt) * 2020-09-11 2023-04-11 Univ Georgia Ácido nucleico, vetor, segmento genômico viral, vírus, composição farmacêutica, método para induzir ou aumentar uma resposta imune contra o vírus influenza, vírus recombinante, método para induzir uma resposta imune em um sujeito em necessidade e polipeptídeo
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN113304267B (zh) * 2021-06-11 2022-03-15 河南大学 肺癌的治疗靶点及其应用
CN114014941B (zh) * 2022-01-10 2022-04-12 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN116549667B (zh) * 2023-05-29 2024-02-09 四川普锐特药业有限公司 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965126A (en) * 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
AU784605B2 (en) * 1999-10-20 2006-05-11 Johns Hopkins University School Of Medicine, The Chimeric immunogenic compositions and nucleic acids encoding them
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
MXPA04008408A (es) * 2002-03-01 2004-11-29 Squibb Bristol Myers Co Mamiferos no humanos, transgenicos, que expresan receptores de la tirosina cinasa activados constitutivamente.
US7709625B2 (en) * 2004-06-10 2010-05-04 The Board Of Regents Of The University Of Texas Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy
AU2005339587B2 (en) * 2005-11-16 2011-11-03 Universidad Nacional Autonoma De Mexico Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
CN101438158A (zh) * 2006-03-06 2009-05-20 阿穆尼克斯股份有限公司 遗传包和其应用
US20080206139A1 (en) * 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
HRP20211788T1 (hr) * 2008-08-26 2022-02-18 City Of Hope Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
HUE032519T2 (en) * 2010-03-26 2017-09-28 Memorial Sloan Kettering Cancer Center Antibodies to MUC16 and a procedure for its use
WO2014090985A1 (en) * 2012-12-13 2014-06-19 Universität Leipzig T-cell modulation by exon skipping
SI3300745T1 (sl) * 2013-02-15 2020-01-31 The Regents Of The University Of California Himerni antigenski receptor in postopki njihove uporabe
JP2016513458A (ja) * 2013-03-10 2016-05-16 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 化学療法耐性免疫細胞
WO2015120363A1 (en) * 2014-02-10 2015-08-13 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
EP3227317A4 (en) 2014-12-02 2018-04-25 Roger Williams Hospital Methods and compositons for treating cancer

Also Published As

Publication number Publication date
UY36418A (es) 2016-06-30
AR102879A1 (es) 2017-03-29
EP3227317A1 (en) 2017-10-11
JP2017537622A (ja) 2017-12-21
WO2016089916A1 (en) 2016-06-09
BR112017011771A2 (pt) 2018-07-10
SG11201704519YA (en) 2017-07-28
US9650428B2 (en) 2017-05-16
EP3227317A4 (en) 2018-04-25
TW201636425A (zh) 2016-10-16
AU2015355084A1 (en) 2017-06-29
SG10202103475XA (en) 2021-05-28
MX2017007272A (es) 2018-06-06
CN107709353A (zh) 2018-02-16
EA201791210A1 (ru) 2017-11-30
US20160151490A1 (en) 2016-06-02
US20180072789A1 (en) 2018-03-15
PH12017501031A1 (en) 2017-11-27
KR20180041087A (ko) 2018-04-23
IL252610A0 (en) 2017-07-31
CA2969714A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
HK1251862A1 (zh) 治療癌症的方法和組合物
IL304820A (en) Preparations and methods for the treatment of cancer
HK1251407A1 (zh) 治療癌症的方法
ZA201804227B (en) Methods of treating cancer
PT3377516T (pt) Composição para o tratamento do cancro
HK1249469A1 (zh) 用RORγ抑制劑治療癌症的方法
SI3200815T1 (sl) Postopki in sestavki za zdravljenje raka
HK1254258A1 (zh) 使用阿吡莫德治療癌症的方法
EP3177292A4 (en) Compounds and methods for treating cancer
HK1250944A1 (zh) 用於治療癌症的方法
IL256523A (en) Compositions and methods for treating cancer
IL246558A0 (en) New methods of cancer treatment
HK1250942A1 (zh) 用於治療癌症的方法
HK1250943A1 (zh) 用於治療癌症的方法
IL255638A (en) Compositions and methods for treating cancer
HK1250958A1 (zh) 用於治療癌症的組合物和方法
GB201414904D0 (en) Materials and methods for treating cancer